Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JZP 898

Next Previous
Drug Profile

JZP 898

Alternative Names: JZP-898; WTX-613

Latest Information Update: 29 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Werewolf Therapeutics
  • Developer Jazz Pharmaceuticals plc; Werewolf Therapeutics
  • Class Antineoplastics; Immunotherapies; Interferons
  • Mechanism of Action Interferon alpha-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Lymphoma
  • Research Haematological malignancies

Most Recent Events

  • 31 Dec 2023 Werewolf Therapeutics has pending patent application for JZP 898 in Australia, Canada, Japan, USA, before December 2023
  • 31 Dec 2023 Werewolf Therapeutics has pending US provisional patent application for certain methods of use with respect to WTX 613 in USA prior to December 2023
  • 07 Nov 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT06108050)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top